Polymorphisms of NRF2 gene correlated with decreased FEV1 in lung cancers of smokers

Sasaki,Hidefumi; Suzuki,Ayumi; Shitara,Masayuki; Hikosaka,Yu; Okuda,Katsuhiro; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/br.2013.83

Polymorphisms of NRF2 gene correlated with decreased FEV1 in lung cancers of smokers

Authors:
- Hidefumi Sasaki
- Ayumi Suzuki
- Masayuki Shitara
- Yu Hikosaka
- Katsuhiro Okuda
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan
Published online on: March 19, 2013 https://doi.org/10.3892/br.2013.83
Pages: 484-488

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The metabolism of xenobiotics plays a fundamental role in smoking‑related lung function loss and the development of pulmonary disease. An NRF2‑dependent response is a key protective mechanism against oxidative stress. In the present study, we evaluated the effect of single nucleotide polymorphisms in NRF2 genes on the level of forced expiratory volume in one second (FEV1) in lung cancers of smokers. We genotyped the status of NRF2 gene polymorphisms in 209 surgically treated lung cancer cases of smokers using TaqMan polymerase chain reaction (PCR). The results demonstrated the mean FEV1 in patients with rs2364723 C/C, C/G and G/G to be 2143.9, 2294.2 and 2335.4 ml, respectively, and there was a tendency towards lower FEV1 in C/C phenotype (P=0.0944). The mean FEV1 was significantly lower in the C/C phenotype (2143.9±566.0 ml) compared to C/G or G/G (2308.9±642.9 ml, P=0.05). The mean FEV1 in patients with rs6726395 A/A, G/A and G/G was 66.7, 71.2 and 72.3%, respectively, and there was a significant difference between A/A and G/G phenotype (P=0.043). A tendency towards a lower mean FEV1 in A/A phenotype (66.7±11.7%) was observed when compared to A/G or G/G (71.9±10.7%, P=0.07). This study demonstrated that an NRF2‑dependent response to cigarette smoking has the potential to affect FEV1 decrease in a lung cancer population. In conclusion, the results have shown that NRF2 genetic changes may play a role in FEV1 loss in smokers with lung cancer.

View Figures

View References

1	Caramori G, Casolari P, Cavallesco GN, Giuffre S, Adcock I and Papi A: Mechanisms involved in lung cancer development in COPD. Int J Biochem Cell Biol. 43:1030–1044. 2011. View Article : Google Scholar : PubMed/NCBI
2	El-Zein RA, Young RP, Hopkins RJ and Etzel CJ: Genetic predisposition to chronic obstructive pulmonary disease and/or lung cancer: important considerations when evaluating risk. Cancer Prev Res. 5:522–527. 2012. View Article : Google Scholar : PubMed/NCBI
3	Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P and Gamble GD: COPD prevalence is increased in lung cancer independence of age, gender and smoking history. Eur Respir J. 34:380–386. 2009. View Article : Google Scholar
4	Wilson DO, Weissfeld JL, Balkan A, et al: Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 178:738–744. 2008. View Article : Google Scholar : PubMed/NCBI
5	Young R and Hopkins R: Lung function predicts lung cancer. Eur Respir J. 35:1421–1422. 2010. View Article : Google Scholar : PubMed/NCBI
6	Mannino DM, Aguayo SM, Petty TL and Redd SC: Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 163:1475–1480. 2003. View Article : Google Scholar : PubMed/NCBI
7	Tockman MS, Anthonisen NR, Wright EC and Donithan MG: Airways obstruction and the risk for lung cancer. Ann Inter Med. 106:512–518. 1987. View Article : Google Scholar : PubMed/NCBI
8	Wasswa-Kintu S, Gan WQ, Man SF, Pare PD and Sin DD: Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 60:570–575. 2005.PubMed/NCBI
9	Young RP, Hopkins RJ and Eaton TE: Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J. 30:616–622. 2007.PubMed/NCBI
10	Burrows B, Knudson RJ, Cline MG, et al: Qualitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis. 115:195–205. 1977.PubMed/NCBI
11	Itoh K, Chiba T, Takahashi S, et al: An Nef2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
12	Rushmore TH and Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II detoxifying enzymes. Curr Drug Metab. 3:481–490. 2002. View Article : Google Scholar : PubMed/NCBI
13	Ngyyen T, Yang CS and Pickett CB: The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med. 37:433–441. 2004. View Article : Google Scholar : PubMed/NCBI
14	Malhorta D, Thimmulappa R, Navas-Acien A, et al: Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med. 178:592–604. 2008. View Article : Google Scholar : PubMed/NCBI
15	Cho HY, Reddy SP and Kleeberger SR: Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal. 8:76–87. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ishii Y, Ito K, Morishima Y, et al: Transcription factor NRF2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol. 175:6968–6975. 2005. View Article : Google Scholar
17	Suzuki M, Betsuyaku T, Ito K, et al: Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 39:673–682. 2008. View Article : Google Scholar : PubMed/NCBI
18	Marzec JM, Christie JD, Reddy SP, et al: Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J. 21:2237–2246. 2007. View Article : Google Scholar : PubMed/NCBI
19	Arisawa T, Tahara T, Shibata T, et al: Nrf2 gene promoter polymorphism and gastric carcinogenesis. Hepatogastroenterology. 55:750–754. 2008.PubMed/NCBI
20	Siedlinski M, Postma DS, Boer JM, et al: Level and course of FEV1 in relation to polymorphisms in NFE2L2 and KEAP1 in the general population. Respir Res. 10:732009. View Article : Google Scholar : PubMed/NCBI
21	Masuko H, Sakamoto T, Kaneko Y, et al: An interaction between Nrf2 polymorphisms and smoking status affects annual decline in FEV1: a longitudinal retrospective cohort study. BMC Med Genet. 12:972011. View Article : Google Scholar : PubMed/NCBI
22	Spitz MR, Wei Q, Dong Q, Amos CI and Wu X: Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev. 12:689–698. 2003.PubMed/NCBI
23	Seibold MA and Schwartz DA: The lung: the natural boundary between nature and nurture. Annu Rev Physiol. 73:457–478. 2011. View Article : Google Scholar : PubMed/NCBI
24	Muller T and Hengstermann A: Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease. Chem Res Toxicol. 25:1805–1824. 2012. View Article : Google Scholar : PubMed/NCBI
25	Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA. 105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
26	Gresner P, Gromadzinska J and Wasowicz W: Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer. Lung Cancer. 57:1–25. 2007. View Article : Google Scholar : PubMed/NCBI
27	Rotunno M, Yu K, Lubin JH, et al: Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One. 4:e56522009. View Article : Google Scholar : PubMed/NCBI
28	Sasaki H, Hikosaka Y, Okuda K, et al: NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J Thorac Oncol. 5:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
29	Rangasamy T, Cho CY, Thimmulappa RK, et al: Genetic ablation of NRF2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest. 114:1248–1259. 2004. View Article : Google Scholar : PubMed/NCBI
30	Yamamoto T, Yoh K, Kobayashi A, et al: Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem Biophys Res Commun. 321:72–79. 2004. View Article : Google Scholar : PubMed/NCBI